Hims & Hers rises after Q1 results beat

Shares of telehealth firm Hims & Hers Health HIMS.N reverse premarket falls to rise as much as 10.7% to $46.35

HIMS posts Q1 revenue of $586.0 million, beating analysts' estimates of $538.2 million - data compiled by LSEG

Co reports Q1 adj profit of 20 cents per share vs estimates of 12 cents

Co sees Q2 revenue to be between $530 million and $550 million, below estimates of $564.6 million

HIMS expects onetime quarter-over-quarter revenue drop in Q2, as it transitions subscribers previously on commercially available dosages of Novo Nordisk's NOVOb.CO semaglutide to options on its or other platforms by end of quarter

Reaffirms full-year revenue forecast of $2.3 billion to $2.4 billion

We suspect that the re-affirmed 2025 and new Q2 forecast is likely "conservative," brokerage BTIG says

Including session's move, stock up ~93% YTD